Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31037651 | 0.99 | TLR7 (0.76) | TLR7TLR8 | |
| SCHEMBL6105985 | 0.90 | TLR7 (0.79) | TLR7TLR8 | |
| SCHEMBL5113045 | 0.89 | TLR8 (0.82) | TLR7TLR8 | |
| SCHEMBL3817941 | 0.89 | TLR7 (0.87) | TLR7TLR8 | |
| SCHEMBL18610767 | 0.89 | TLR7 (0.68) | TLR7TLR8 | |
| SCHEMBL30346094 | 0.89 | TLR7 (0.68) | TLR7TLR8 | |
| SCHEMBL483696 | 0.89 | TLR7 (0.68) | TLR7TLR8 | |
| SCHEMBL6106596 | 0.89 | TLR7 (0.77) | TLR7TLR8 | |
| SCHEMBL1043163 | 0.88 | TLR8 (0.74) | TLR7TLR8 | |
| SCHEMBL1951699 | 0.88 | TLR7 (0.93) | TLR7TLR8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119455004-A | Compositions, methods and uses comprising antibody-TLR agonist conjugates | AMBRX公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-119455003-A | Compositions, methods and uses comprising antibody-TLR agonist conjugates | AMBRX公司 | 2025-02-18 | — | — | CN | disclosed |
| CN-113660957-B | Compositions, methods and uses comprising antibody-TLR agonist conjugates | AMBRX公司 | 2024-12-13 | — | — | CN | disclosed |
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | AMBRX, INC. (US) | 2023-09-28 | — | — | US | disclosed |
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | AMBRX, INC. (US) | 2023-09-28 | — | — | US | disclosed |
| CN-116457023-A | antibody-TLR agonist conjugates, methods and uses thereof | AMBRX公司 | 2023-07-18 | — | — | CN | disclosed |
| EP-3589631-B1 | IMIDAZO[4,5-C]RING COMPOUNDS CONTAINING GUANIDINE SUBSTITUTED BENZAMIDE GROUPS | 3M INNOVATIVE PROPERTIES CO (US) | 2021-07-21 | — | — | EP | disclosed |
| EP-3344622-B1 | GUANIDINE SUBSTITUTED, FUSED 1H-IMIDAZO[4,5-C]PYRIDINE COMPOUNDS USEFUL IN THE TREATMENT OF VIRAL AND NEOPLASTIC DISEASES | 3M INNOVATIVE PROPERTIES CO (US) | 2021-07-07 | — | — | EP | disclosed |
| CN-108026092-B | Guanidine-substituted imidazo [4,5-c ] ring compounds | 3M创新有限公司 | 2021-01-26 | — | — | CN | disclosed |
| US-10766896-B2 | Imidazo[4,5-c] ring compounds containing guanidine substituted benzamide groups | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2020-09-08 | — | — | US | disclosed |
| EP-1341790-A2 | SULFONAMIDO ETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2003-09-10 | — | — | EP | disclosed |
| EP-1341792-A2 | AMIDO ETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M Innovative Properties Company (US) | 2003-09-10 | — | — | EP | disclosed |
| US-20030158192-A1 | Urea substituted imidazoquinoline ethers | 3M INNOVATIVE PROPERTIES COMPANY | 2003-08-21 | — | — | US | disclosed |
| US-20030139441-A1 | Sulfonamido ether substituted imidazoquinolines | UBS AG, STAMFORD BRANCH | 2003-07-24 | — | — | US | disclosed |
| US-20030130518-A1 | Urea substituted imidazoquinoline ethers | COLEY PHARMACEUTICAL GROUP, INC. | 2003-07-10 | — | — | US | disclosed |
| US-20030096835-A1 | Amido ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2003-05-22 | — | — | US | disclosed |
| US-20020193396-A1 | Sulfonamido ether substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2002-12-19 | — | — | US | disclosed |
| WO-2002046191-A2 | UREA SUBSTITUTED IMIDAZOQUINOLINE ETHERS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2002-06-13 | — | — | WO | disclosed |
| WO-2002046190-A2 | SULFONAMIDO ETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2002-06-13 | — | — | WO | disclosed |
| WO-2002046188-A2 | AMIDO ETHER SUBSTITUTED IMIDAZOQUINOLINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230302150-A1 | ANTIBODY-TLR AGONIST CONJUGATES, METHODS AND USES THEREOF | TLR3, TLR1, TLR9 | TLR7 4/4885TLR8 9/4885 |
| US-20030158192-A1 | Urea substituted imidazoquinoline ethers | IRF3, EIF2AK2, IFNG | TLR7 84/4885TLR8 273/4885 |
| US-20030139441-A1 | Sulfonamido ether substituted imidazoquinolines | IFNG, IRF3, IL2 | TLR7 24/4885TLR8 50/4885 |
| US-10766896-B2 | Imidazo[4,5-c] ring compounds containing guanidine substituted benzamide groups | IL4, IFNG, IFNAR1 | TLR7 105/4885TLR8 213/4885 |
| US-20030130518-A1 | Urea substituted imidazoquinoline ethers | IRF3, EIF2AK2, IFNG | TLR7 84/4885TLR8 273/4885 |
| US-20030096835-A1 | Amido ether substituted imidazoquinolines | IFNG, IRF3, EIF2AK2 | TLR7 14/4885TLR8 51/4885 |
| US-20020193396-A1 | Sulfonamido ether substituted imidazoquinolines | IFNG, IRF3, IL2 | TLR7 24/4885TLR8 50/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.